EarlyCDT-Lung is a blood test that measures the levels of seven autoantibodies to tumour-associated antigens linked to lung cancer. Credit: Louis Reed on Unsplash.

UK-based immunodiagnostics developer Oncimmune, in alliance with Genostics, has initiated a multi-centre clinical trial of its EarlyCDT-Lung test in the People’s Republic of China.

Designed to enable early detection of lung cancer, EarlyCDT-Lung is a blood test that measures the levels of seven autoantibodies to tumour-associated antigens associated with lung cancer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

As these seven autoantibodies are known to be elevated in all types of lung cancer and from the earliest stage, the test is expected to be able to identify all types of the cancer at all stages (I-IV).

The test runs on a simple enzyme-linked immunosorbent assay (ELISA) platform. Oncimmune noted that EarlyCDT-Lung could detect the cancer nearly four years or more before clinical diagnosis using standard care pathways.

Oncimmune CEO Adam Hill said: “This study is part of our ongoing programme to support the introduction of EarlyCDT-Lung in China, which is progressing to schedule.

“We welcome this initiative and the commitment of our partner Genostics in supporting the introduction of EarlyCDT-Lung into what is one of the world’s largest markets.”

The multi-centre, case-control trial will involve an extended panel of autoantibodies in order to include variations in the biomarkers expressed on cancer cells in Asian populations.

“We welcome this initiative and the commitment of our partner Genostics.”

It will be conducted for around 1,000 early lung cancers at five academic health centres in China. Professor Bai from the Pulmonary Medicine department at Zhongshan Hospital, Fudan University, will lead the study.

Results from the study are expected to be available in the fourth quarter of this year. The company anticipates that the study data will support its application for EarlyCDT-Lung approval in China.

EarlyCDT-Lung is also being studied by the National Health Service (NHS) in a randomised trial for the early detection of lung cancer using biomarkers.